Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, experts of all ages from both domestic and international arenas engaged in discussions and exchanges on the latest developments and hot topics in lymphoma diagnosis and treatment. "Oncology Frontier - Hematology Frontier" had the privilege to interview Professor Aichun Liu, Director of the Department of Hematology and Lymphoma at Harbin Medical University Cancer Hospital, regarding his perspectives and opinions on the overall treatment strategy for relapsed/refractory B-cell lymphoma, as well as sharing his team's research plans and management experiences in lymphoma.